



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1,
Rd No.23, Wagle Ind. Estate Thane West, Thane –400604, Maharashtra, INDIA
Phn: 022 66177400/401; E-mail: bajaj@bajajhealth.com

Date: April 17, 2020.

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001.

Dear Sir/Madam,

Ref :Script Id “BAJAJHCARE”, Script Code “539872”

Sub :Press Release on FDA Approval for manufacturing Hydroxychloroquine Sulphate Bulk Drug (API) and formulation of its tablets.

We enclose a copy of the Press Release that is being issued by the Company in connection with FDA approval for manufacturing Hydroxychloroquine Sulphate Bulk Drug (API) and formulation for its tablets.

**For and behalf of Board of Directors of
Bajaj Healthcare Limited**

**Company Secretary
Aakash Keshari**



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1,
Rd No.23, Wagle Ind. Estate Thane West, Thane –400604, Maharashtra, INDIA
Phn: 022 66177400/401; E-mail: bajaj@bajajhealth.com

PRESS RELEASE

April 17, 2020

***Bajaj Healthcare Limited Ramp-Up Production
of “Game Changer” Coronavirus Drug
Hydroxychloroquine Sulphate***

Bajaj Healthcare Limited (BHL), one of the leading manufacturers of API and formulations announced that it has received FDA approval for manufacturing Hydroxychloroquine Sulphate Bulk Drug (API) and formulation for its tablets. Hydroxychloroquine Sulphate has been recommended by several countries, including the US, with limited dosage for Covid-19 patients and as a preventive for high-risk individuals like healthcare workers.

BHL will commence its own production of Hydroxychloroquine Sulphate API in the next 3 weeks at its state-of-art manufacturing facilities based at 588, Savli – Karachia Road, At & Post – Gothada, Tal – Savli, Dist. – Vadodara, Gujarat-391776 and it is estimate to produce 15 Mts of API per month.

BHL has started the production of Hydroxychloroquine FDF (Tablets) at R S No – 1818, Manjusar, Vadodara – Savli Road, Taluka- Savli, Vadodara, Gujarat—391775 and is estimated to produce approximately 15 million tablets of Hydroxychloroquine Sulphate.

Mr. Sajankumar Bajaj, Chairman & Managing Director of the Company said, “This is a very critical time in our fight against COVID-19. With our existing capabilities and our ability to fast-track production of **Hydroxychloroquine Sulphate and its tablets**, we are well-positioned to partially meet the prospective demand and will continue to do everything we can to support the healthcare needs of our fellow citizens and human race globally.”

The growing global threat of COVID-19 requires optimum commitment by everyone involved in public health. BHL takes its responsibility seriously and is committed to continuing to work with governments, partners and others to identify areas of need where our manufacturing expertise and capacity can be of service.

India manufactures 70 percent of the world's supply of Hydroxychloroquine Sulphate. As the COVID-19 pandemic widens across the world, and there has been a sudden interest in an anti-malarial and anti-inflammatory drug called Hydroxychloroquine **Sulphate**.



Hydroxychloroquine tablets are approved by the U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus. We look forward to working with governments and health authorities globally to ensure patient access to this medicine as and where needed.

About Bajaj Healthcare Limited (BHL),

Bajaj Healthcare Limited a leading manufacturer of API, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 3 units are dedicated to API, 2 units to Intermediates and 1 unit for formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

For further information on the Company, please visit: www.bajajhealth.com

For further information contact:

| | |
|--------------|--|
| Name: | Mr. Anil Jain |
| Designation: | Managing Director |
| Contact | +91 98925 27675 |
| Email : | bajaj@bajajhealth.com |

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCES.